MILFORD, Pa., Oct. 7, 2014 /PRNewswire/ -- Manzo
Pharmaceuticals, Inc. (OTCPink:FOGCD), today announced that after
discussions with the Food and Drug Administration, it has been
determined that its long lasting lactose digestive aid,
Lacto-Freedom™, will not need FDA approval to be released to the
public. The FDA considers the probiotic to be a dietary
"supplement", and therefore outside the scope of a very long and
expensive FDA approval process that would be required if the
treatment was deemed to be a "drug." This will greatly reduce
the time to market for Lacto-Freedom and enable Manzo
Pharmaceuticals to market the product to millions of people who
suffer from lactose intolerance much sooner.
"We are ecstatic about this determination because what would
have taken years, can now be done in months. The time and
expense saved by this development is monumental for the company,
and for the people who suffer from this life altering
complication," Said the company's CEO, Kenneth Manzo. Manzo stated that the company is
still going through with a smaller human trial to confirm that it
is safe and works the way it is intended in humans, but the time
and expense of this test does not even compare to the strict
testing and approval process needed when FDA approval is
required.
The company is taking the necessary steps to put a small human
study in place and hopes to have it off the ground in a few months.
There has been a lot of change and progress within the company
recently as it has undergone a name change and a small change in
corporate stock structure. The company feels the release of
Lacto-Freedom could be the most important healthcare breakthrough
ever for millions of lactose intolerance sufferers worldwide.
With the release of the product on the horizon, it's no surprise
that a lot of people are very excited about the company's future
prospects.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, is a specialty pharmaceutical company
engaged in the research, development, and testing of patented and
non-patented solutions and remedies. Most notably is a patented
probiotic for people who suffer from Lactose Intolerance, and a
natural remedy for colic in babies. For more information follow the
company on twitter at @manzopharma, and visit
www.manzopharma.com.
DISCLAIMER: This Press Release may contain certain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The Company has tried,
whenever possible, to identify these forward-looking statements
using words such as "anticipates," "believes," "estimates,"
"expects," "plans," "intends," "potential" and similar expressions.
These statements reflect the Company's current beliefs and are
based upon information currently available to it. Accordingly, such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which could cause the Company's
actual results, performance or achievements to differ materially
from those expressed in or implied by such statements. The Company
undertakes no obligation to update or advise in the event of any
change, addition or alteration to the information catered in this
Press Release including such forward-looking statements.
SOURCE Manzo Pharmaceuticals, Inc.
